Close Menu

NEW YORK – Lung cancer diagnostics firm OncoCyte said after the close of the market on Thursday that it posted $555,000 in revenues for the third quarter compared to none a year ago.

The Alameda, California-based firm beat the analysts' average estimate of $370,000.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.